

Real-World Evidence in Type 2 Diabetes: Focus on SGLT2 Inhibitors and GLP-1 Receptor Agonists

OVERVIEW

This supplement to *The American Journal of Managed Care*[®] provides real-world evidence on the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in the management of type 2 diabetes (T2D) reflective of current clinical practice in the United States. Studies explore the generalizability of enrollment criteria of the cardiovascular outcomes trials (CVOTs) to assess the applicability to real-world T2D populations; real-world evidence supporting the use of dapagliflozin as add-on therapy to metformin with or without other oral antidiabetic agents for patients with T2D; and real-world prescribing patterns of GLP-1 receptor agonists in patients without T2D which provides insights for managed care policy making and formulary management.

TABLE OF CONTENTS

Participating Faculty	S130
Reports	
A Retrospective Real-World Study of Dapagliflozin Versus Other Oral Anti-Diabetes Drugs Added to Metformin in Patients with Type 2 Diabetes	S132
<i>Huan Huang, PhD; Kelly F. Bell, PharmD, MSPhr; Ray Gani, PhD; Cathy W. Tugwell, RN, BSN; James M. Eudicone, MS, MBA; and Michelle R. Krukus-Hampel, MA</i>	
Eligibility Varies Among the Four Sodium-Glucose Cotransporter-2 Inhibitor Cardiovascular Outcomes Trials: Implications for the General Type 2 Diabetes US Population	S138
<i>Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD</i>	
Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population	S146
<i>Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Kelly F. Bell, PharmD, MSPhr; Devin M. Enhoffer, PharmD; Keith Latham, PharmD; and Jennifer B. Green, MD</i>	
Comparison of Low-Dose Liraglutide Use Versus Other GLP-1 Receptor Agonists in Patients Without Type 2 Diabetes	S156
<i>Eric T. Wittbrodt, PharmD, MPH; James M. Eudicone, MS, MBA; Sepehr Farahbakhshian, MS; and Carrie McAdam-Marx, PhD, MSCI, RPh</i>	
Appendices	S165

EDITORIAL & PRODUCTION

Senior Director

Naomi Musaji, PharmD

Senior Clinical Project Manager

Ida Delmendo

Clinical Project Manager

Ted Pigeon

Managing Medical Writer

Angelia Szwed

Project Coordinator

Andrea Szeszko

Copy Chief

Jennifer Potash

Copy Editors

Maggie Shaw

Rachelle Laliberte

Designer

Julianne Costello

SALES & MARKETING

Senior Vice President, Managed Markets

Jeff Prescott, PharmD

Director of Sales

Gil Hernandez

National Account Managers

Elise Maier

Robert Foti

Ryan O'Leary

OPERATIONS & FINANCE

Director of Circulation

Jon Severn
circulation@mjhassoc.com

Vice President of Finance

Leah Babitz, CPA

Controller

Katherine Wyckoff

CORPORATE

Chairman and CEO

Mike Hennessy, Sr

Vice Chairman

Jack Lepping

President

Mike Hennessy, Jr

Chief Financial Officer

Neil Glasser, CPA/CFE

Chief Marketing Officer

Warren Dardine

Chief Digital Strategy Officer

Steve Ennen

Vice President of Editorial Services and Production

Kerrie Keegan

Vice President of Digital Media

Jung Kim

Chief Creative Officer

Jeff Brown

Vice President, Live Events

Tom Tolvé

Director of Human Resources

Shari Lundenberg

Copyright © 2018 by Managed Care & Healthcare Communications, LLC

FACULTY

Kelly F. Bell, PharmD, MSPhr

Director, Health Economics and Outcomes Research (at time of study)
AstraZeneca
Wilmington, Delaware

Devin M. Enhoffer, PharmD

Postdoctoral Fellow
Ernest Mario School of Pharmacy
Rutgers University
Piscataway Township, New Jersey

James M. Eudicone, MS, MBA

Director, Health Economics and Outcomes Research Statistics & Programming
AstraZeneca
Wilmington, Delaware

Sepehr Farahbakhshian, MS

Associate Director of Managed Markets (at time of study)
AstraZeneca
Wilmington, Delaware

Ray Gani, PhD

Senior Research Scientist (at time of study)
IQVIA
Reading, Berkshire, United Kingdom

Jennifer B. Green, MD

Associate Professor of Medicine
Division of Endocrinology
Duke University Medical Center
Durham, North Carolina

Huan Huang, PhD

Scientific Advisor, Real-World Insights
IQVIA
Cambridge, Massachusetts

Michelle R. Krukus-Hampel, MA

Scientific Advisor, Advisory Analytics
IQVIA
Cambridge, Massachusetts

Keith Latham, PharmD

US Medical Affairs
AstraZeneca
Wilmington, Delaware

Carrie McAdam-Marx, PhD, MSCI, RPh

Associate Professor, Director
Pharmaceutical Evaluation & Policy Division
University of Arkansas for Medical Sciences (UAMS)
Little Rock, Arkansas

Cathy W. Tugwell, RN, BSN

Senior Regional Scientific Manager (at time of study)
AstraZeneca
Wilmington, Delaware

Eric T. Wittbrodt, PharmD, MPH

Director, Health Economics and Outcomes Research
US Medical Affairs
AstraZeneca
Wilmington, Delaware



MJH
Associates, Inc.

FACULTY DISCLOSURES

The authors report relationships with the following organizations:

Kelly F. Bell, PharmD, MSPhr

EMPLOYMENT
GlaxoSmithKline

James M. Eudicone, MS, MBA

EMPLOYMENT
AstraZeneca

EMPLOYER CONFLICT OF INTEREST
AstraZeneca: Subject matter pertains to an AstraZeneca product

Sepehr Farahbakhshian, MS

EMPLOYMENT
Employment with AstraZeneca (at time of study)

STOCK OWNERSHIP
AstraZeneca

Ray Gani, PhD

CONSULTANT
AstraZeneca

EMPLOYMENT
Quintiles (at time of study), which received funding from AstraZeneca

Jennifer B. Green, MD

CONSULTANT
Boehringer Ingelheim Pharmaceuticals, Inc
Daiichi Sankyo Company, Limited
Merck Sharp & Dohme Corp
Novo Nordisk Inc

RESEARCH SUPPORT
AstraZeneca
GlaxoSmithKline plc
Intarcia Therapeutics, Inc

Huan Huang, PhD

EMPLOYMENT
IQVIA

EMPLOYER CONFLICT OF INTEREST
IQVIA, which received research funding to conduct study from AstraZeneca

Michelle R. Krukas-Hampel, MA

EMPLOYMENT
IQVIA

EMPLOYER CONFLICT OF INTEREST
IQVIA, which received research funding to conduct study from AstraZeneca

Keith Latham, PharmD

EMPLOYMENT
AstraZeneca

STOCK OWNERSHIP
AstraZeneca

Carrie McAdam-Marx, PhD, MSCI, RPh

RESEARCH SUPPORT
AstraZeneca
Sanofi

Eric T. Wittbrodt, PharmD, MPH

EMPLOYMENT
AstraZeneca

EMPLOYER CONFLICT OF INTEREST
AstraZeneca: Subject matter pertains to AstraZeneca products (an SGLT2 inhibitor [article 2] and a GLP-1 receptor agonist [articles 3 and 4])

Devin M. Enhoffer, PharmD, and **Cathy W. Tugwell, RN, BSN**, report no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of *The American Journal of Managed Care*®, Cranbury, New Jersey.